Cerus (NasdaqGM:CERS) Q4 2025 Earnings call March 02, 2026 04:30 PM ET Company ParticipantsKevin Green - CFOTim Lee - Head of Investor RelationsVivek Jayaraman - COOWilliam Greenman - President and CEOConference Call ParticipantsBill Bonello - Senior Research AnalystMark Massaro - Managing Director and Senior Equity Research AnalystOperatorGood day, ladies and gentlemen. Thank you for standing by. Welcome to the Cerus Corporation fourth quarter and full year 2025 earnings conference call. Please be advised ...

Belite Bio (NasdaqCM:BLTE) Q4 2025 Earnings call March 02, 2026 04:30 PM ET Company ParticipantsHao-Yuan Chuang - CFOHendrik Scholl - CMONathan Mata - Chief Scientific OfficerSophie Hunt - Media and Investor RelationsTom Lin - Chairman and CEOConference Call ParticipantsBoris Peaker - Senior Equity Research AnalystBruce Jackson - Equity Research AnalystGary Nachman - Managing Director and Senior Research AnalystJudah Guber - AnalystMarc Goodman - Senior Research AnalystMichael Okunewitch - Senior Research A ...

Gaia (NasdaqGM:GAIA) Q4 2025 Earnings call March 02, 2026 04:30 PM ET Company ParticipantsJirka Rysavy - ChairmanKiersten Medvedich - CEONed Preston - CFOYonathan Nuta - COOConference Call ParticipantsGeorge Kelly - Senior Research AnalystJames Sidoti - Senior Equity AnalystRyan Meyers - Senior Research AnalystOperatorGood afternoon. Welcome to Gaia's fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. Joining us today from Gaia are Jirka Rysavy, Kiersten ...

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $27.3 million, a decrease of $16.5 million year-over-year, primarily due to lower volume on Army programs [30] - Gross margin for Q4 2025 was 20.4%, down from 37.4% in the same period last year, attributed to one-time items in Q4 2024 [30] - Net loss for Q4 2025 was $5.8 million, significantly improved from a net loss of $138.2 million in the comparable period, mainly due to a non-cash gain on derivatives and an income tax benefit related to the Ask Sage acquisition [31][32] - Adjusted EBITDA for Q4 was -$10.3 million compared to $2 million in the prior year, driven by lower revenue and increased expenses [32] Business Line Data and Key Metrics Changes - The company completed the acquisition of Ask Sage on December 31, 2025, which is expected to enhance capabilities in defense and security sectors [8] - CargoSeer was also acquired, aimed at improving customs and security operations through AI technology [10] - R&D expenses increased from $2.3 million in Q4 2024 to $4.8 million in Q4 2025, reflecting ongoing investments in new capabilities [31] Market Data and Key Metrics Changes - The company is expanding its international footprint, particularly in the UAE, where it has established a presence and formed partnerships to enhance operational effectiveness [7][8] - The U.S. government is expected to increase its defense budget significantly, potentially reaching $1.5 trillion, which could benefit the company’s market positioning [13] Company Strategy and Development Direction - The company aims to strengthen its financial position and expand its international presence while pursuing strategic acquisitions [5][19] - Focus areas include national security and travel and trade markets, leveraging AI capabilities to enhance operational efficiency [18][19] - The company plans to capitalize on catalytic M&A opportunities to enhance its service capabilities in national security and trade [22] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of adapting to the evolving geopolitical landscape and the increasing demand for advanced technologies in national security [12][18] - The company is well-positioned to support U.S. government initiatives and capitalize on funding opportunities driven by recent legislative measures [13][19] - Future revenue guidance for 2026 is projected between $135 million and $165 million, representing approximately 17% growth from 2025 [33] Other Important Information - The company transitioned out of emerging growth company status, enhancing its internal controls and compliance [29] - A proxy solicitation to authorize 500 million shares of common stock is underway, with strong shareholder support [34] Q&A Session Summary Question: What are the expectations for revenue growth in 2026? - The company projects full-year 2026 revenue between $135 million and $165 million, reflecting growth from recent acquisitions and market opportunities [33] Question: How is the company addressing the recent changes in the defense budget? - Management indicated that the anticipated increase in the defense budget could provide significant opportunities for the company, aligning with its core strengths in national security [13] Question: What is the strategy for integrating recent acquisitions? - The company is focused on fully integrating Ask Sage and CargoSeer to enhance capabilities and deliver mission-specific solutions to customers [22][24]

Financial Data and Key Metrics Changes - For Q4 2025, R&D expenses were $14.6 million, up from $7.3 million in Q4 2024, primarily due to DRAGON II trial expenses and lower Australian R&D tax incentives [6][8] - SG&A expenses increased to $13.5 million from $4.2 million in Q4 2024, driven by higher share-based compensation and professional service fees [8][10] - The net loss for Q4 2025 was $25.3 million, compared to $10.1 million in Q4 2024, while the non-GAAP net loss was $13.6 million, up from $5.9 million in Q4 2024 [8][9] - For the full year, R&D expenses totaled $45.4 million, compared to $29.9 million in 2024, and SG&A expenses were $38.9 million, up from $10.1 million in 2024 [9][10] - The full year net loss was $77.6 million, compared to $36.1 million in 2024, with a non-GAAP net loss of $38.7 million, up from $27.2 million in 2024 [10][11] Business Line Data and Key Metrics Changes - The company achieved significant milestones in 2025, including the successful phase 3 DRAGON trial, which demonstrated a 36% reduction in the growth rate of atrophy lesions compared to placebo [4][5] - Enrollment in the DRAGON II study reached 72 subjects, with expectations to finalize between 72 and 75 subjects [4] - The phase 3 PHOENIX trial in GA completed enrollment with 430 subjects [5] Market Data and Key Metrics Changes - The company closed the year with $772.6 million in cash equivalents, significantly up from $145.2 million at the end of 2024, positioning it well for future objectives [11] Company Strategy and Development Direction - The primary focus for 2026 is the planned NDA submission to the FDA in Q2 2026, with commercialization preparations for Stargardt disease already underway [5][6] - The company aims to build its organization in sales, market access, medical affairs, marketing, regulatory, and operations [6] - The company is prioritizing the U.S. market for regulatory submissions, with plans to follow up with EMA and other regions post-U.S. approval [33][59] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the transformative potential of Tinlarebant as a treatment for Stargardt disease [3][5] - The management noted that the absence of existing treatments for Stargardt disease could facilitate a straightforward launch process [27] - The company anticipates launching by Q1 2027, with a focus on genetic testing and patient awareness as key factors for success [26][27] Other Important Information - The company completed a $402 million public offering in Q4 2025, which supports its commercialization and pipeline development efforts [5] - Management indicated that pricing for the drug is still under consideration, with expectations that it could exceed the average rare disease drug price of approximately $350,000 [19] Q&A Session Summary Question: NDA submission process and cash usage - The NDA will be a rolling submission, with DRAGON II data relevant only for Japan. The company expects to spend about $150 million on R&D activities and $150-$200 million on commercialization over the next three years [14][15] Question: Pricing guidance and NDA gating items - Pricing is still being determined, but the company expects to set a price higher than the average for rare disease drugs. The key gating item before NDA submission is the finalization of the clinical study report [19][21] Question: Launch timing and challenges - The company expects to launch by Q1 2027, with a sales team focused on genetic testing and brand awareness. Challenges include patient and physician awareness of the treatment [26][27] Question: Ex-U.S. regulatory strategy - The company prioritizes the U.S. FDA submission, with plans to follow up with EMA and other regions after securing U.S. approval [33][59] Question: Stargardt disease prevalence and awareness - The company estimates about 53,000 patients in the U.S. are affected by Stargardt disease, and having a treatment available is expected to increase awareness and diagnosis of undiagnosed patients [64][66] Question: Pediatric studies - The company has an approved pediatric investigational plan with EMA to study safety and efficacy in children aged 3 to 11, with plans to expand into the pediatric population [68][70]

Financial Data and Key Metrics Changes - Total revenues for 2025 reached $233.8 million, a record level for the company, representing a 16% increase from 2024 [16] - Product revenue increased by 14% for both the fourth quarter and the full year, exceeding prior guidance of $202 million-$204 million [16] - Product gross margin for Q4 was 51.5%, down from 53.9% in the same period last year, impacted by higher production costs and inflationary pressures [20][21] - GAAP net loss for Q4 was $2.2 million, with a full-year loss of $15.6 million, down 25% from the prior year [24] Business Line Data and Key Metrics Changes - The U.S. platelet franchise is estimated to hold a market share in the mid-60s, with strong growth expected due to a new group purchasing agreement with the Blood Centers of America [10][11] - IFC product revenue grew by nearly 40% in Q4 compared to the same period last year, with a full-year growth of approximately 80% [18] - EMEA product revenue increased by 25% in Q4 and 14% for the full year, driven by strong demand in both platelet and plasma franchises [17] Market Data and Key Metrics Changes - The INITIATE study in Germany represents a $30 million annual platelet opportunity, with enrollment starting in January 2026 [12][41] - Demand for IFC increased by over 50% in Q4 compared to the same period last year, indicating strong market traction [13] - The company estimates that IFC market adoption exited 2025 at around 7%, with expectations to increase penetration significantly by the end of 2026 [19] Company Strategy and Development Direction - The company aims to establish the INTERCEPT Blood System as the global standard of care for transfused blood components, with ongoing investments in innovation and regulatory approvals [6][7] - The recent launch of the INT200 device is seen as a foundational element for global growth, with positive customer feedback reinforcing the company's leadership in transfusion medicine [7] - The strategic partnership with the Blood Centers of America is expected to enhance market penetration and facilitate broader discussions across the network [11][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth into 2026, reaffirming product revenue guidance of $224 million-$228 million, representing a year-over-year increase of 9%-11% [19] - The company anticipates a third consecutive year of positive adjusted EBITDA, driven by revenue growth and disciplined expense management [25] - Management acknowledged ongoing inflationary pressures and import tariffs as potential challenges to gross margins in 2026 [21] Other Important Information - The company ended 2025 with nearly $83 million in cash and short-term investments, maintaining prudent cash management while funding growth initiatives [25] - Operating cash flow for the full year was $4.8 million, consistent with expectations despite increased investments [26] Q&A Session Summary Question: Can you elaborate on the BCA agreement and its impact on blood centers? - Management highlighted that the BCA agreement allows leveraging their supply chain and contracting platforms, which is expected to drive penetration in the U.S. platelet market [30][31] Question: What are the expectations for cash flow in 2026? - Management indicated that cash flow generation is expected to continue, with ongoing investments in inventory to support anticipated growth [34][35] Question: Can you provide an update on the INITIATE study in Germany? - The INITIATE study is expected to lead to increased revenue contributions starting in 2027, with the market opportunity estimated at $30 million annually [41][42] Question: What is the status of red blood cells in Europe? - The regulatory submission for red blood cells is under review, with potential approval expected in the first half of 2027 [44] Question: What is the growth potential in the Middle East? - Management noted significant opportunities in Saudi Arabia and other countries, with INTERCEPT platelets being influenced by U.S. standards [48][49]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.8 million, down from $9.2 million in Q4 2024, reflecting lower transient volumes and construction impacts [16][19] - For the full year 2025, total revenue decreased by 5.2% to $35.1 million from $37 million in 2024 [19] - Net operating income (NOI) for Q4 2025 was $5.3 million, compared to $5.5 million in Q4 2024, while full year NOI was $20.7 million, down from $22.6 million in 2024 [18][19] - Adjusted EBITDA for Q4 2025 remained flat at $3.9 million, while for the full year it decreased to $14.3 million from $15.8 million in 2024 [18][20] Business Line Data and Key Metrics Changes - Contract parking ended 2025 with over 6,700 contracts, achieving same-store sales growth of 10% year-over-year [6] - Residential parking contracts increased approximately 60% year-over-year in 2025, diversifying revenue sources [10] - Transient revenue volumes declined by 6% in 2025, but transient rates increased, indicating resilience [11] Market Data and Key Metrics Changes - The company noted a positive shift in demand dynamics, particularly in markets with a return to office momentum [9] - Cincinnati and Nashville markets are expected to see improvements as construction disruptions have been resolved [11][36] Company Strategy and Development Direction - The company executed phase one of its asset rotation strategy, selling over $30 million of non-core assets [12][13] - Focus remains on strengthening the balance sheet and reducing the cost of capital through line of credit paydowns and stock repurchase programs [14][21] - The company aims to enhance its portfolio by transitioning to intelligent infrastructure, leveraging data from its assets [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in growth for 2026, supported by the reopening of venues and increased contract parking volumes [5][24] - The company acknowledged the uncertainty surrounding AI's impact on work and productivity but emphasized the enduring value of physical infrastructure [14][15] - Management highlighted the importance of operational enhancements and targeted strategies to improve transaction flow and revenue [26] Other Important Information - The company has repurchased over 1.6 million shares at an average price of $3.25 per share, indicating a commitment to shareholder value [21] - Guidance for 2026 includes expected revenue of $35 million to $38 million, representing a potential 4% growth over 2025 [21][23] Q&A Session Summary Question: Can you provide details on the dispositions and what is still to close? - The company has one asset remaining to close this quarter, anticipated within 14 to 20 days, with more targeted conversations for future sales [32][33] Question: What is the impact of local disruptions in markets like Cincinnati and Nashville? - Management noted improvements in Cincinnati with increased contract revenue and attendance at events, while Nashville is expected to see a gradual return to pre-disruption levels [36] Question: How has weather impacted the portfolio in Q1? - Weather disruptions were noted but deemed nominal overall, with January typically being a slow month [39][43] Question: What is the status of the transition from leases to management contracts? - The remaining transitions are expected to occur over the next 24 months, with minimal impact anticipated [54] Question: Can you update on the asset acquisition pipeline? - The focus remains on paying down the line of credit in the near term, with future acquisitions being evaluated based on capital allocation [60]

Nuvation Bio (NYSE:NUVB) Q4 2025 Earnings call March 02, 2026 04:30 PM ET Speaker8Hello, welcome to Nuvation Bio's fourth quarter and full year 2025 financial results and corporate update call. Today's call is being recorded, and a replay will be available. All participants are currently in a listen-only mode. A brief question and answer session will follow the prepared remarks. Now, I'd like to turn the call over to J.R. DeVita, Executive Director of Corporate Development and Investor Relations at Nuvation ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 totaled approximately $198,000, up from $62,000 in the prior year quarter, driven by hardware sales and services from the Fab-One facility [15][16] - Operating expenses for Q4 2025 were $22.1 million, compared to $8.9 million in the same quarter last year, reflecting growth in personnel for R&D, engineering, and sales [15][16] - The net loss for Q4 2025 was $1.6 million, or $0.01 loss per share, significantly reduced from a net loss of $51.2 million in Q4 2024 [16][17] - For the full year 2025, the net loss was $18.7 million, or $0.11 per share, compared to a loss of $68.5 million, or $0.73 per share, in 2024 [17] Business Line Data and Key Metrics Changes - The foundry services business began generating early revenue and customer engagement, contributing to the overall revenue growth [4][6] - The acquisition of Lumina Semiconductor Inc. is expected to enhance design, fabrication, and packaging capabilities, contributing to revenue in 2026 [5][15] Market Data and Key Metrics Changes - The company is focused on expanding its global reach through industry engagement and participation in conferences, indicating a strategy to capture market opportunities [9][10] - The demand for energy-efficient room temperature photonic and quantum solutions is expected to grow, positioning the company favorably within these trends [12][13] Company Strategy and Development Direction - The company aims to build a vertically integrated photonics and quantum optics platform to support scalable commercial applications across various sectors, including AI and cybersecurity [4][10] - A multi-year technology roadmap has been formalized, focusing on scalable room temperature photonic and quantum products [10][11] - The company is transitioning from a development stage to a commercial manufacturing-driven platform business, emphasizing the importance of low power consumption and smaller form factors [11][12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term fundamentals for photonics, quantum technology, and AI infrastructure, despite recent market volatility [12][13] - The focus remains on executing the strategy, advancing the technology roadmap, and building a sustainable commercial business [12][19] Other Important Information - The company ended 2025 with cash and cash equivalents of $738 million and investments of $783 million, totaling approximately $1.52 billion in assets [18] - The integration of Lumina Semiconductor Inc. is underway, with a focus on aligning teams and processes to accelerate growth [9][19] Q&A Session Summary Question: What are the expected revenues from the LSI acquisition? - Management indicated that projected revenue from LSI could be in the $20 million-$25 million range, but they do not provide specific revenue guidance [27] Question: What are the expected costs associated with LSI? - Management noted that costs will be incurred as they work on integrating LSI, and profitability at this scale is not expected in the near term [29][31] Question: What are the critical milestones for 2026? - Key milestones include successfully integrating Lumina Semiconductor, advancing the quantum product portfolio, and growing the team for system-level engineering [48] Question: Which market is most exciting for the company this year? - Management expressed particular excitement about thin-film lithium niobate technology and its potential for quantum communications [52][53] Question: Are there plans for further M&A? - The company is following a disciplined approach to M&A, focusing on acquisitions that accelerate their roadmap and build their customer base [55]

Riot Platforms (NasdaqCM:RIOT) Q4 2025 Earnings call March 02, 2026 04:30 PM ET Speaker7Good day, and thank you for standing by. Welcome to Riot Platforms' Fiscal Year 2025 earnings conference call. Please note that all participants have been placed in listen-only mode until the question and answer session begins following the company's presentation of its prepared remarks. Please also be advised that today's call is being recorded. I would now like to hand the conference over to Joshua Kane, Head of Invest ...